Sarepta Therapeutics (SRPT) creates RNA-based drugs for the treatment of serious and life threatening diseases. Its most advanced candidate is an intravenously delivered treatment for Duchenne Muscular Dystrophy [DMD]. In addition to the promising DMD program, the company also has drugs for the treatment of ebola, Marburg and influenza viruses in clinical Phase 1 trials.
RNA drugs without the R
The company uses a phosphorodiamidate morpholino oligomer [PMO] antisense platform that allows for a diverse range of therapeutic candidates. The technology is far simpler than its name implies. Natural RNA is a string of nucleic acid bases (adenine, cytosine, guanine, and thymine) held together by backbone of recurring ribose rings. Sarepta's PMOs use the same nucleic acid bases,...
Only subscribers can access this article, which is part of the PRO research library covering 3,792 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: